122509-72-2

Basic information

• Product Name: 6-Chloro-5-fluoroindole
• Synonyms: 6-CHLORO-5-FLUOROINDOLE;6-Chloro-5-fluoroindole ,98%;6-Chloro-5-fluoro-1H-indole;- 6-chloro-5-fluroindole;1H-Indole,6-chloro-5-fluoro-
• CAS NO: 122509-72-2
• Molecular Formula: C₈H₅ClFN
• Molecular Weight: 169.58
• EINECS: 1312995-182-4
• Product Categories: Indoles and derivatives;Indole
• Mol File: 122509-72-2.mol

Chemical Properties

• Melting Point: 105-107°C
• Boiling Point: 299.8 °C at 760 mmHg
• Flash Point: 135.1 °C
• Appearance: /
• Density: 1.436 g/cm³
• Vapor Pressure: 0.0122mmHg at 25°C
• Refractive Index: 1.432
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.26±0.30(Predicted)
• CAS DataBase Reference: 6-Chloro-5-fluoroindole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-fluoroindole(122509-72-2)
• EPA Substance Registry System: 6-Chloro-5-fluoroindole(122509-72-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-37/38-41-36/37/38
• Safety Statements: 26-39-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 122509-72-2(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C7H10F2O2/c8-7(9)3-1-5(2-4-7)6(10)11/h5H,1-4H2,(H,10,11)

Upstream product

• 709007-52-3 [2-(4-chloro-5-fluoro-2-nitrophenyl)vinyl]dimethylamine 
• 85462-59-5 2-bromo-5-chloro-4-fluoroaniline 
• 96202-57-2 6-Chloro-5-fluoro-1H-indole-2,3-dione 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 118664-99-6 1-chloro-2-fluoro-4-methyl-5-nitrobenzene 
• 100487-74-9 6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one 
• 1026638-79-8 (R,S)-1-(trifluoroacetyl)-6-chloro-5-fluoro-3-hydroxy-2,3-dihydro-1H-indole 
• 367-21-5 3-chloro-4-fluorophenylamine 
• 259860-00-9 2-fluoro-4-methyl-5-nitro-phenylamine 
• 452-80-2 2-fluoro-4-methylaniline 
• 496916-77-9 3-chloro-4-fluoro-6-vinylaniline 
• 1027185-20-1 1-(6-Chloro-5-fluoro-indol-1-yl)-2,2,2-trifluoro-ethanone 

Downstream Products

• 1193314-23-6 cipargamin 
• 205584-67-4 2,3-dihydro-6-chloro-5-fluoro-1H-indole 
• 920023-30-9 6-chloro-5-fluoro-1H-indole-3-carboxylic acid 
• 172078-39-6 6-Chloro-5-nitro-indole 

Relevant articles and documents

Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.

The syntheses of a series of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2- b]pyrrol-1-yl)-1-methylethylamines are reported. The binding affinities of the compounds at 5HT2C and 5HT2A receptors (79% homology in the transmembrane domain)

From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3βinhibitors that suppress proliferation and survival of pancreatic cancer cells

Recent studies have demonstrated that glycogen synthase kinase 3β (GSK-3β) is overexpressed in human colon and pancreatic carcinomas, contributing to cancer cell proliferation and survival. Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl) maleimides, potent GSK-3β inhibitors. Some of these compounds show picomolar inhibitory activity toward GSK-3β and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2). Selected GSK-3β inhibitors were tested in the pancreatic cancer cell lines MiaPaCa-2, BXPC-3, and HupT3. We determined that some of these compounds, namely compounds 5, 6, 11, 20, and 26, demonstrate antiproliferative activity against some or all of the pancreatic cancer cells at low micromolar to nanomolar concentrations. We found that the treatment of pancreatic cancer cells with GSK-3β inhibitors 5 and 26 resulted in suppression of GSK-3β activity and a distinct decrease of the X-linked inhibitor of apoptosis (XIAP) expression, leading to significant apoptosis. The present data suggest a possible role for GSK-3β inhibitors in cancer therapy, in addition to their more prominent applications in CNS disorders.

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives

The present invention relates to Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R7 are as defined herein. The invention

Indoline derivatives as 5-HT2C receptor agonists

A series of 1-(1-indolinyl)-2-propylamines was synthesised and evaluated as 5-HT2C receptor agonists for the treatment of obesity. The general methods of synthesis of the precursor indoles are described. The functional efficacy and radioligand

Use of a modified Leimgruber-Batcho reaction to prepare 6-chloro-5-fluoroindole

An efficient synthesis of the title indole, the heterocyclic core of the standard 5-HT2C receptor agonist Ro 60-0175, via a modified Leimgruber-Batcho indole synthesis is presented. The process can be used to make > 100 g quantities of the targ

Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands

For use in therapy a chemical compound of formula (I), wherein R1to R3are independently selected from hydrogen and alkyl; R4to R7are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4to R7is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesity; chemical compounds of formula (I) other than compounds wherein R7is hydroxy.

Preparation of 6-chloro-5-fluoroindole via the use of palladium and copper-mediated heterocyclisations

The title indole, the heterocyclic core of the 5-HT2C receptor agonist Ro 60-0175, was prepared by a modification to the Stille indole synthesis, or by the method of Gonzalez and co-workers.

4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents

This invention relates to certain 4-aminoquinazolines and the pharmaceutically acceptable salts and stereoisomers thereof, the formula whereof are described herein. The compounds are useful for the treatment of hyperproliferative diseases, particularly as anti-cancer agents.

Indole derivatives

The invention releates to indole derivatives of the formula STR1 wherein R 1 to R 4 are, independently, hydrogen, halogen, lower-alkyl, cycloalkyl or trifluoromethyl, R 5 and R 6 are, independently, hydrogen, halogen, lower-alkyl, cycloalkyl, trifluoromet